“Switching from Dupilumab to Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab: Efficacy and Safety Results from the Phase 3b/4 LEVEL UP Study” (2024) SKIN The Journal of Cutaneous Medicine, 8(6), p. s451. doi:10.25251/skin.8.supp.451.